• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Boehringer Ingelheim (Group)

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development. *

 

	Start	1885-01-01 established
	Industry	pharmaceutical
	Person	Boehringer, Christian (Boehringer 201207 Chairman of Shareholders’ Committee)
	Person 2	Barner, Andreas (Boehringer)
	Region	Ingelheim
	Country	Germany
	Street	173 Binger Str.
	City	55216 Ingelheim
	Tel	+49-6132-770
		Address record changed: 2018-07-24
Basic data	Employees	I: 50,001 to 100,0 (2019-12-31)
	Currency	EUR
	Annual sales	18,997,000,000 (sales, net, consolidated (2019) 2019-12-31)
	Profit	2,721,000,000 (2019-12-31)
	Cash	2,195,000,000 (2019-12-31)
		* Document for �About Section�:
		Record changed: 2020-09-21

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Boehringer Ingelheim. (9/17/20). "Press Release: Boehringer Ingelheim and Mirati Therapeutics Annonce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor". Ingelheim & San Di...
• [2] Boehringer Ingelheim. (9/11/20). "Press Release: Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia". Ingelheim & New...
• [3] Boehringer Ingelheim. (9/7/20). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy". Ingelheim & Sydney....
• [4] BiomX Inc.. (9/2/20). "Press Release: BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease". Ness Ziona....
• [5] Autifony Therapeutics Ltd.. (8/26/20). "Press Release: Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme". Stevenage....
• [6] Numab Therapeutics AG. (7/7/20). "Press Release: Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases". Wädenswil & Ingelheim....
• [7] Boehringer Ingelheim. (7/2/20). "Press Release: Boehringer Ingelheim Launches External Innovation Hub in China". Ingelheim....
• [8] Boehringer Ingelheim. (6/8/20). "Press Release: New Consortium EUbOPEN Will Provide Tools to Unlock Disease Biology. 66 Million Euros to Generate Open-access Chemical Tools". Frankfurt & Ingelheim....
• [9] Boehringer Ingelheim. (5/14/20). "Press Release: Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio". Ingelheim & Toronto, ON....
• [10] Insilico Medicine. (4/14/20). "Press Release: Insilico Enters into a Research Collaboration with Boehringer Ingelheim to Apply Novel Generative Artificial Intelligence System for Discovery of Potential Therapeutic Targets". Hong Kong....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.